bioRxivNeurosciencePreprint
SorCS1 promotes synaptic and cognitive resilience despite amyloid pathology in Alzheimer's disease model mice
Nayoung YiiD, Alfred Kihoon Lee, Farin B. BourojeniiD, Manni WangiD, Mai InagakiiD, Hideto TakahashiiD
Abstract
Alzheimer's disease (AD) lacks effective therapies despite extensive efforts targeting amyloid {beta} (A{beta}) and its precursor processing. Synapse loss is the strongest correlate of cognitive decline, driven partly by A{beta} oligomers (A{beta}Os), which bind multiple synaptic membrane proteins including the synaptic organizer neurexin and disrupt synaptic integrity and function. The protein sorting receptor SorCS1 blocks interactions between A{beta}Os and {beta}-isoforms of neurexins ({beta}-Nrxns), but its therapeutic relevance in vivo remains unclear. Using 5xFAD mice, which overproduce A{beta}Os, combined with forebrain specific neuronal SorCS1 overexpression, we show that SorCS1 preserves working memory, synaptic integrity, and basal excitatory transmission without altering amyloid deposition, in part by restoring synaptic {beta}-Nrxn expression. SorCS1 also reduces tau hyperphosphorylation in 5xFAD synaptosomes and binds the tau kinase GSK3{beta}. These results identify SorCS1 as an AD resilience promoting factor that maintains synaptic connectivity and attenuates tau pathology, revealing a therapeutic strategy that operates independently of amyloid reduction.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SorCS1 inhibits amyloid-β binding to neurexin and rescues amyloid-β-induced synaptic pathology
Alfred Kihoon Lee, Nayoung Yi, … Hideto Takahashi·Life Science AlliancePeer-reviewed·Jan 25, 2023
- Social and Contextual Memory Impairments Induced by Amyloid-β Oligomers are Rescued by Sigma-1 Receptor Activation
Souhail Djebari, Raquel Jiménez‐Herrera, … Juan D. Navarro‐López·Biomedicine & PharmacotherapyPeer-reviewed·Feb 24, 2025
- Antibody-based immunotherapy targeting FAM19A5 reverses synaptic loss and improves cognitive function in Alzheimer's disease.
Hanbyul Kim, Sangjin Yoo, … Jae Young Seong·bioRxiv·Nov 22, 2023
- SFRP1 upregulation causes hippocampal synaptic dysfunction and memory impairment
Guadalupe Pereyra, María Inés Mateo, … Paola Bovolenta·Cell ReportsPeer-reviewed·Apr 1, 2025
- The Alzheimer's disease risk gene SORL1 is a regulator of excitatory neuronal function
C. Andrew Williams, Shannon E. Rose, … Jessica E. Young·Alzheimer s & DementiaPeer-reviewed·Sep 1, 2026
- Quantitative analysis of synaptic pathology and neuroinflammation: an initial study in a female rhesus monkey model of the “synaptic” phase of Alzheimer’s disease
Danielle Beckman, Kristine Donis‐Cox, … John H. Morrison·bioRxiv·Jan 19, 2018